Skip to content
Back to meeting Original
Karine Tawagi MD· @DrKarineTawagi · X·· 1 day agoScore70
Body

#PAPMET2 trial @maughanonc
although closed early d/t slow enrollment, still very meaningful to show more data to support IO/TKI preferred over TKI in papillary RCC

36 pts enrolled
Higher PFS & ORR with doublet

Results of STELLAR-304, SAMETA & AXIPAP are pending! #ESMO26

54 views · 5 likes · 0 reposts · 0 replies

Source: Karine Tawagi MD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.